King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Ayman Saad
Dr. Ayman Saad is a Consultant Haematologist specialising in acute myeloid leukaemia, myelodysplastic syndrome (MDS), haematopoietic stem cell transplantation, and CAR-T cell therapy — a leading acute leukaemia specialist in Riyadh, Saudi Arabia with clinical research focus on chronic graft-versus-host disease, CAR-T outcomes, and rare bone marrow failure syndromes. His recent work includes research on ruxolitinib for sclerotic cGVHD, CAR-T cell prognostic factors, and ERCC6L2 bone marrow failure.
- Consultant Haematologist specialising in Acute Leukaemia, MDS, BMT, and CAR-T cell therapy
- Lead or co-author on recent research covering CAR-T prognostic impact, GVHD, and bone marrow failure
- Principal investigator on a multicentre phase II trial of ruxolitinib for steroid-refractory sclerotic cGVHD
- Expertise in haematopathology, flow cytometry, and minimal residual disease (MRD) monitoring
- Published contributor to ERCC6L2 bone marrow failure and sinusoidal obstruction syndrome research
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
Fellowships & Special Training
- Fellowship in Adult Haematology
- Fellowship in Haematopoietic Stem Cell Transplantation
- Advanced Training in Haematopathology and Flow Cytometry
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- American Society of Hematology (ASH) — Member
- European Society for Blood and Marrow Transplantation (EBMT) — Member
Areas of Expertise
Major Conditions Treated
- Acute Myeloid Leukaemia (AML)
- Acute Lymphoblastic Leukaemia (ALL)
- Myelodysplastic Syndrome (MDS)
- Chronic Myeloid Leukaemia (CML)
- Myeloproliferative Neoplasms
- Aplastic Anaemia and Bone Marrow Failure (Including ERCC6L2)
- Graft-versus-Host Disease (Acute and Chronic)
- Sinusoidal Obstruction Syndrome
- Relapsed/Refractory B-Cell Lymphoma (CAR-T Candidates)
Sub-specialties
- Acute Leukaemia & MDS Management: Evidence-based induction and consolidation chemotherapy, venetoclax-azacitidine regimens, and targeted FLT3/IDH inhibitors — a trusted acute leukaemia specialist in Riyadh for international patients.
- Stem Cell Transplantation & CAR-T: Autologous, allogeneic, and haploidentical HSCT; CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies.
- cGVHD & Transplant Complications: Principal investigator on ruxolitinib phase II trial for steroid-refractory sclerotic chronic GVHD; expertise in sinusoidal obstruction syndrome and inotuzumab-related hepatotoxicity management.
Advanced Procedures & Treatments
- Induction and Consolidation Chemotherapy for AML/ALL
- Venetoclax-Azacitidine Regimens for AML and MDS
- FLT3 / IDH1 / IDH2 Inhibitor Therapy
- Allogeneic and Haploidentical HSCT
- CD19 CAR-T Cell Therapy
- Ruxolitinib for Steroid-Refractory Chronic GVHD
- Defibrotide for Sinusoidal Obstruction Syndrome
- Minimal Residual Disease (MRD) Monitoring via Flow Cytometry
Professional Experience
Current Affiliation
- Consultant Haematologist, Acute Leukaemia Section — King Faisal Specialist Hospital & Research Centre (KFSHRC) Oncology Centre, Riyadh, Saudi Arabia (Present)
Past Affiliations
- Fellowship training in Adult Haematology and Stem Cell Transplantation — completed prior to KFSHRC consultancy
Academic & Research Roles
- Principal Investigator — multicentre phase II trial of ruxolitinib for sclerotic cGVHD (2022)
- Contributing Investigator — CD19 CAR-T cell therapy prognostic studies
- Faculty — KFSHRC Haematology clinical and education programmes
Key Achievements
- Lead or co-author on Blood (2024) publications including CAR-T prognostic impact (144:7153), ERCC6L2 bone marrow failure (144:5706), and sinusoidal obstruction syndrome / inotuzumab (144:7306)
- Principal investigator on phase II trial of ruxolitinib for steroid-refractory sclerotic cGVHD (2022)
- Expertise spans haematopathology, flow cytometry, and MRD assessment
- Active in international collaborations on CAR-T outcomes and GVHD
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Saudi Society of Haematology
Research & Publications
Published Papers (Selected)
- Saad A, et al. Ruxolitinib for Steroid-Refractory Sclerotic Chronic GVHD — Multicentre Phase II Trial. 2022.
- Saad A, et al. Prognostic Impact of CD19 CAR-T Cell Therapy Factors. Blood. 2024;144:7153.
- Saad A, et al. ERCC6L2-Associated Bone Marrow Failure. Blood. 2024;144:5706.
- Saad A, et al. Sinusoidal Obstruction Syndrome and Inotuzumab Hepatotoxicity. Blood. 2024;144:7306.
Ongoing Research & Clinical Interests
- CAR-T cell therapy outcomes and prognostic factors
- Chronic graft-versus-host disease therapy
- Rare bone marrow failure syndromes (ERCC6L2)
- Sinusoidal obstruction syndrome prevention and treatment
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Bone Marrow Biopsy & Aspirate | ₹8,000 – ₹25,000 | $100 – $300 |
| Chemotherapy (per cycle) | ₹40,000 – ₹2,00,000 | $480 – $2,400 |
| Autologous Stem Cell Transplant | ₹12,00,000 – ₹18,00,000 | $14,500 – $21,700 |
| Allogeneic Stem Cell Transplant | ₹18,00,000 – ₹30,00,000 | $21,700 – $36,100 |
| CAR-T Cell Therapy | ₹1,50,00,000 – ₹4,00,00,000 | $180,000 – $480,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Ayman Saad use in Adult Haematology — Acute Leukaemia & Stem Cell Transplantation treatment?
Dr. Ayman Saad uses advanced acute leukaemia and transplant technologies including venetoclax-azacitidine regimens for AML and MDS, FLT3/IDH1/IDH2 targeted inhibitors, allogeneic and haploidentical HSCT, CD19 CAR-T cell therapy, ruxolitinib for steroid-refractory sclerotic chronic GVHD, defibrotide for sinusoidal obstruction syndrome, and minimal residual disease (MRD) monitoring via flow cytometry. Virtual consultations and remote second opinions are also available to international patients through Cancer Rounds.
2. What conditions does Dr. Ayman Saad specialize in treating?
Dr. Ayman Saad specialises in Acute Leukaemia, Haematopoietic Stem Cell Transplantation, and CAR-T cell therapy, treating acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), chronic myeloid leukaemia (CML), myeloproliferative neoplasms, aplastic anaemia (including ERCC6L2), graft-versus-host disease, sinusoidal obstruction syndrome, and relapsed/refractory B-cell lymphomas considered for CAR-T. International patients seeking the best acute leukaemia and transplant doctor in India or Saudi Arabia benefit from his CAR-T and cGVHD expertise.
3. How do I book an appointment with Dr. Ayman Saad?
Appointments with Dr. Ayman Saad can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Ayman Saad?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Ayman Saad, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Ayman Saad offer second opinions for Adult Haematology — Acute Leukaemia & Stem Cell Transplantation cases?
Yes. Second opinion consultations for Acute Leukaemia, GVHD, and CAR-T cases can be arranged via Cancer Rounds, enabling international patients to review transplant eligibility, CAR-T candidacy, and steroid-refractory GVHD options with Dr. Ayman Saad.
